Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
What are you searching for?
Enclose phrases in quotes. Use a + to require a term in results and - to exclude terms.
Example: +water -Europe
Subscribe
Research
Biotech
Clinical Data
Venture Capital
Deals
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Cell & Gene Therapy
COVID-19
Emerging Biopharma
Podcasts
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
breast cancer
Biotech
Phase 2 attrition jumps amid scale-back in trial activity
The wave of pipeline prioritization initiatives implemented last year has manifested in a jump in terminations of phase 2 clinical trials.
Nick Paul Taylor
Jan 18, 2023 6:42am
FDA clears MedCognetics’ AI for breast cancer screening
Dec 16, 2022 11:51am
QT Imaging takes the SPAC track in $151M go-public deal
Dec 12, 2022 10:51am
AstraZeneca-Daiichi lay down phase 1 breast cancer data for ADC
Dec 9, 2022 9:50am
Pfizer's $1B protein degradation bet yields 3% response rate
Nov 22, 2022 9:40am
Pfizer discards eczema, NASH and breast cancer programs
Nov 1, 2022 9:50am
